Skip to Content

Boehringer Ingelheim receives FDA Approval for new Atrovent HFA

RIDGEFIELD, CONN., November 18, 2004 -- Boehringer Ingelheim Pharmaceuticals, Inc. announced FDA has approved new Atrovent HFA (ipratropium bromide HFA) Inhalation Aerosol indicated as a bronchodilator for maintenance treatment of bronchospasm associated with COPD (chronic obstructive pulmonary disease), including chronic bronchitis and emphysema.

Atrovent HFA is a new drug formulation that was developed to provide COPD patients a therapeutic benefit comparable to Atrovent (ipratropium bromide) (CFC) Inhalation Aerosol, a leading treatment for COPD.

New Atrovent HFA is formulated with a non-chlorofluorocarbon (CFC) propellant called HFA (hydrofluoroalkane) that was developed in response to the Montreal Protocol on Substances that Deplete the Ozone Layer. The Montreal Protocol, a global agreement to protect the ozone layer, requires the removal of ozone depleting substances including CFC propellants. The agreement recognizes the special needs of the world's respiratory patients who require inhalation therapy, and the essential role of the pressurized metered-dose inhaler, and therefore grants these products an exemption until they can be replaced by non-CFC alternatives. Boehringer Ingelheim supports the Montreal Protocol and will replace the company's CFC inhalers once the replacement products are available.

Source: Boehringer Ingelheim Pharmaceuticals

Posted: November 2004